Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

7 Results

8+ YEARS POOLED ANALYSIS: ADHERENCE AND HIV INCIDENCE IN 6000 WOMEN ON F/TDF FOR PrEP

Background: Daily emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP) substantially reduces HIV acquisition. This multinational pooled analysis summarizes data from >6000 women followed since F/TDF for PrEP approval in 2012 to better understand adherence and HIV prevention. Methods: We obtained demographic, adherence, and HIV-1 status for cisgender women on F/TDF for PrEP at…

REACTOGENICITY AMONG PEOPLE LIVING WITH HIV AFTER mRNA-1273 VACCINE IN UBUNTU STUDY

Background: The tolerability of mRNA COVID-19 vaccines among people living with HIV (PLWH) has been understudied in vaccine trials. CoVPN 3008 (Ubuntu) is the largest multicenter Phase 3 efficacy trial of mRNA vaccines in sub-Saharan Africa. Methods: We enrolled adults age ≥18 years living with HIV or another comorbidity associated with severe COVID-19. Previously vaccinated…

INTEGRATING PrEP INTO ANTENATAL CARE FOR HIV-NEGATIVE PREGNANT WOMEN IN SOUTH AFRICA

Background: HIV incidence is high during pregnancy and postpartum. Oral PrEP was introduced in South Africa in 2016 and guidelines were updated in 2021 to include PrEP for pregnant and postpartum women. Methods: The PrEP in pregnancy and postpartum (PrEP-PP) study is an observational cohort in one public health clinic in Cape Town, South Africa.…

PBPK MODEL PREDICTION OF LONG-ACTING CAB AND RPV CONCENTRATIONS IN PREGNANCY

Background: The pharmacokinetics (PK) of cabotegravir (CAB) long-acting and rilpivarine (RPV) long-acting has not been prospectively studied in pregnancy. Physiologically-based pharmacokinetic models (PBPK) offer the ability to incorporate physiologic pregnancy-associated changes and drug specific characteristics to predict the concentration exposure during pregnancy. Methods: We used a published maternal-fetal PBPK model by Dallmann et. al. in…

PREGNANCY AND BIRTH OUTCOMES FOLLOWING ORAL PrEP USE BY OBJECTIVE LEVELS OF TDF/FTC

Background: TDF and FTC have been evaluated for safety among pregnant and lactating people taking PrEP. Prior safety studies measured exposure using self-reported recent adherence, which may over or under-report actual use. This is one of the first studies to compare pregnancy and birth outcomes using objective levels of tenofovir diphosphate (TDF-DP) in dried blood…

SAFETY OF HETEROLOGOUS mRNA-1273 BOOST AFTER Ad26.COV2.S PRIME IN SOUTH AFRICA

Background: Given the paucity of data on safety and effectiveness of mRNA COVID-19 booster vaccinations in lower income settings with high HIV prevalence, we evaluated a heterologous mRNA-1273 (Moderna) boost after priming with 1 or 2 doses of Ad26.COV2.S (Janssen, Johnson & Johnson) vaccine among health care workers (HCWs) in South Africa. Methods: SHERPA is…

PK & SAFETY OF ABC/3TC DISPERSIBLE TABLETS & LPV/r GRANULES IN NEONATES: PETITE STUDY

Background: No oral solid fixed-dose combination (FDC) antiretroviral dispersible formulations are available for HIV prevention or treatment from birth. Neonates could benefit from existing pediatric antiretroviral solid formulations. We evaluated the pharmacokinetics (PK) and safety of pediatric ABC/3TC dispersible tablets and LPV/r (2-in-1) granules in term neonates exposed to HIV, birth weights ≥2.0 to £4.0…